Andrea Bassig
Family · Lockport, NYNPI 1205411881
Payments from drug & device makers
Across 265 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$662
- Novo Nordisk$572
- Lilly USA, LLC$480
- AstraZeneca$454
- GSK$273
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$255
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,661100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $662 |
| Novo Nordisk | 37 | $572 |
| Lilly USA, LLC | 21 | $480 |
| AstraZeneca | 26 | $454 |
| GSK | 15 | $273 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $255 |
| Boehringer Ingelheim | 13 | $231 |
| Novartis | 7 | $153 |
| Exact Sciences | 7 | $142 |
| Pfizer | 8 | $142 |
| Dexcom, Inc. | 8 | $137 |
| AbbVie | 5 | $113 |
| Corcept Therapeutics | 6 | $112 |
| Bayer | 7 | $103 |
| Astellas Pharma US Inc | 6 | $100 |
| Amneal Pharmaceuticals LLC | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Insulet Corporation | 2 | $43 |
| Seqirus USA Inc | 2 | $40 |
| Mannkind Corporation | 2 | $38 |
| Tonix Medicines, Inc. | 1 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Abbott | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Viatris Specialty LLC | 1 | $15 |
| Merck | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$125
How this compares
$4,661 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 20 | $22,420 |
| XareltoRivaroxaban | 11 | $17,301 |
| EliquisApixaban | 11 | $12,762 |
| OzempicSemaglutide | 12 | $10,674 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,407 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,582 |
| Levothyroxine Sodium | 66 | $793 |
| Rosuvastatin Calcium | 46 | $783 |
| Atorvastatin Calcium | 49 | $732 |
| Omeprazole | 28 | $501 |
| Metoprolol Succinate | 21 | $457 |
| Lisinopril | 60 | $455 |
| Levetiracetam | 21 | $430 |
| Gabapentin | 29 | $363 |
| Potassium Chloride | 29 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $480 | $22,42020 claims |
| Johnson & JohnsonXarelto | $14 | $17,30111 claims |
| PfizerEliquis | $142 | $12,76211 claims |
| Novo NordiskOzempic | $572 | $10,67412 claims |
| GSKTrelegy Ellipta | $273 | $9,40711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $73 | $79366 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $18814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in Lockport
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.